AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.